SEATTLE CHILDREN'S HOSPITAL

The Phase III AALL1731 trial showed Blincyto (blinatumomab) significantly improved three-year disease-free survival (DFS) in pediatric patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) when added to chemotherapy, with a 61% decrease in relapse risk. The trial's interim analysis led to early termination due to the observed benefit, highlighting Blincyto's potential as a transformative treatment in this patient population.

A clinical trial combining standard chemotherapy with blinatumomab for newly diagnosed B-ALL in children showed a 61% reduction in relapse or death risk, significantly improving disease-free survival rates, marking a new standard of care in childhood cancer treatment.

Be Biopharma announces updates at ASH Annual Meeting, including BeCoMe-9 trial poster on BE-101, a BCM for Hemophilia B, and an oral presentation on BCM platform versatility in genetic disease and oncology.

Blinatumomab, a bispecific T-cell engager, combined with chemotherapy significantly improves three-year disease-free survival rates in pediatric B-cell acute lymphoblastic leukemia patients, according to the AALL1731 study. The study found a 96% DFS rate with the combination therapy versus 87.9% with chemotherapy alone. Despite rare but serious side effects and high costs, the FDA's approval of blinatumomab for pediatric patients offers hope for improved treatment outcomes.

Blinatumomab added to chemotherapy significantly improves 3-year disease-free survival in children with B-cell acute lymphoblastic leukemia, reducing the hazard ratio for disease recurrence by 61%.

Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk B-cell acute lymphoblastic leukemia (B-ALL), with a 3-year DFS of 96%.

Adding BLINCYTO to chemotherapy significantly improves disease-free survival in pediatric patients with B-cell acute lymphoblastic leukemia, with a 3-year DFS of 96% compared to 87.9% with chemotherapy alone.

Adding BLINCYTO (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL), with a 3-year DFS of 96% compared to 87.9% with chemotherapy alone.

A clinical trial combining chemotherapy with blinatumomab for B-cell acute lymphoblastic leukemia (B-ALL) in children showed a 61% reduction in relapse risk, significantly improving disease-free survival rates, marking a new standard of care in childhood cancer treatment.

Adding BLINCYTO (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL), with a 3-year DFS of 96% compared to 87.9% with chemotherapy alone.